Xiidra

— THERAPEUTIC CATEGORIES —
  • Dry eye

Xiidra Generic Name & Formulations

General Description

Lifitegrast 5%; oph soln.

Pharmacological Class

Lymphocyte function-associated antigen-1 (LFA-1) antagonist.

How Supplied

Single-use containers (0.2mL)—60

Manufacturer

Generic Availability

NO

Mechanism of Action

Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. However, the exact mechanism of action of lifitegrast in dry eye disease is not known.

Xiidra Indications

Indications

Signs and symptoms of dry eye disease (DED).

Xiidra Dosage and Administration

Adult

Instill 1 drop twice daily (~12hrs apart) in each eye.

Children

<17yrs: not established.

Xiidra Contraindications

Not Applicable

Xiidra Boxed Warnings

Not Applicable

Xiidra Warnings/Precautions

Warnings/Precautions

Remove contact lens prior to use; may reinsert 15mins after administration. Pregnancy. Nursing mothers.

Xiidra Pharmacokinetics

See Literature

Xiidra Interactions

Not Applicable

Xiidra Adverse Reactions

Adverse Reactions

Instillation site irritation, dysgeusia, decreased visual acuity; hypersensitivity.

Xiidra Clinical Trials

See Literature

Xiidra Note

Not Applicable

Xiidra Patient Counseling

See Literature